Eleanor Ramos - Net Worth and Insider Trading

Eleanor Ramos Net Worth

The estimated net worth of Eleanor Ramos is at least $3 Million dollars as of 2024-06-06. Eleanor Ramos is the Chief Medical Officer of Provention Bio Inc and owns about 70,000 shares of Provention Bio Inc (PRVB) stock worth over $2 Million. Eleanor Ramos is also the Chief Medical Officer of Global Blood Therapeutics Inc and owns about 11,000 shares of Global Blood Therapeutics Inc (GBT) stock worth over $753,390. Details can be seen in Eleanor Ramos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Eleanor Ramos has not made any transactions after 2021-12-03 and currently still holds the listed stock(s).

Transaction Summary of Eleanor Ramos

To

Eleanor Ramos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Eleanor Ramos owns 2 companies in total, including Provention Bio Inc (PRVB) , and Global Blood Therapeutics Inc (GBT) .

Click here to see the complete history of Eleanor Ramos’s form 4 insider trades.

Insider Ownership Summary of Eleanor Ramos

Ticker Comapny Transaction Date Type of Owner
PRVB Provention Bio Inc 2021-12-03 Chief Medical Officer & COO
GBT Global Blood Therapeutics Inc 2015-12-22 Chief Medical Officer

Eleanor Ramos Latest Holdings Summary

Eleanor Ramos currently owns a total of 2 stocks. Among these stocks, Eleanor Ramos owns 70,000 shares of Provention Bio Inc (PRVB) as of December 3, 2021, with a value of $2 Million and a weighting of 69.89%. Eleanor Ramos also owns 11,000 shares of Global Blood Therapeutics Inc (GBT) as of December 22, 2015, with a value of $753,390 and a weighting of 30.11%.

Latest Holdings of Eleanor Ramos

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRVB Provention Bio Inc 2021-12-03 70,000 24.98 1,748,600
GBT Global Blood Therapeutics Inc 2015-12-22 11,000 68.49 753,390

Holding Weightings of Eleanor Ramos


Eleanor Ramos Form 4 Trading Tracker

According to the SEC Form 4 filings, Eleanor Ramos has made a total of 4 transactions in Provention Bio Inc (PRVB) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Provention Bio Inc is the acquisition of 5,201 shares on December 3, 2021, which cost Eleanor Ramos around $33,755.

According to the SEC Form 4 filings, Eleanor Ramos has made a total of 0 transactions in Global Blood Therapeutics Inc (GBT) over the past 5 years. The most-recent trade in Global Blood Therapeutics Inc is the acquisition of 11,000 shares on December 22, 2015, which cost Eleanor Ramos around $230,230.

Insider Trading History of Eleanor Ramos

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Eleanor Ramos Trading Performance

GuruFocus tracks the stock performance after each of Eleanor Ramos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Eleanor Ramos is -13.52%. GuruFocus also compares Eleanor Ramos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Eleanor Ramos within 3 months outperforms 1 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Eleanor Ramos's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Eleanor Ramos

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -2.86 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -0.71 LIMIT LIMIT LIMIT LIMIT LIMIT

Eleanor Ramos Ownership Network

Ownership Network List of Eleanor Ramos

No Data

Ownership Network Relation of Eleanor Ramos

Insider Network Chart

Eleanor Ramos Owned Company Details

What does Provention Bio Inc do?

Who are the key executives at Provention Bio Inc?

Eleanor Ramos is the Chief Medical Officer & COO of Provention Bio Inc. Other key executives at Provention Bio Inc include 10 percent owner Sessa Capital (master), L.p. , director & 10 percent owner & Chief Scientific Officer Francisco Leon , and director & 10 percent owner & President and CEO Ashleigh Palmer .

Provention Bio Inc (PRVB) Insider Trades Summary

Over the past 18 months, Eleanor Ramos made no insider transaction in Provention Bio Inc (PRVB). Other recent insider transactions involving Provention Bio Inc (PRVB) include a net sale of 299,617 shares made by Francisco Leon , a net sale of 5,190,549 shares made by Sessa Capital (master), L.p. , and a net sale of 100,000 shares made by Ashleigh Palmer .

In summary, during the past 3 months, insiders sold 0 shares of Provention Bio Inc (PRVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,594,666 shares of Provention Bio Inc (PRVB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,594,666 shares.

Provention Bio Inc (PRVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Provention Bio Inc Insider Transactions

No Available Data

Eleanor Ramos Mailing Address

Above is the net worth, insider trading, and ownership report for Eleanor Ramos. You might contact Eleanor Ramos via mailing address: Zymogenetics, Inc., 1201 Eastlake Avenue E, Seattle Wa 98102.

Discussions on Eleanor Ramos

No discussions yet.